Article
Obesity Variants in the GIPR Gene Are not Associated With Risk of Fracture or Bone Mineral Density.
The Journal of clinical endocrinology and metabolism - 12 Jul 2024
Styrkarsdottir Unnur, Tragante Vinicius, Stefansdottir Lilja, Thorleifsson Gudmar, Oddsson Asmundur, Sørensen Erik, Erikstrup Christian, Schwarz Peter, Jørgensen Henrik Løvendahl, Lauritzen Jes Bruun, Brunak Søren, Knowlton Kirk U, Nadauld Lincoln D, Ullum Henrik, Pedersen Ole Birger Vesterager, Ostrowski Sisse Rye, Holm Hilma, Gudbjartsson Daniel F, Sulem Patrick, Stefansson Kari
Abstract excerpt
CONTEXT: It is not clear if antagonizing the GIP (glucose-dependent insulinotropic polypeptide) receptor (GIPR) for treatment of obesity is likely to increase the risk of fractures, or to lower bone mineral density (BMD) beyond what is expected with rapid weight loss. OBJECTIVE: The objective of this study was to investigate the risk of fracture and BMD of sequence variants in GIPR that reduce the activity of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
